Search - tctmd.com

Displaying 141 - 160 of 307

Sort: Relevancy | Date

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

Todd Neale

August 27, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

Women With Early Menopause See Higher Heart Failure, AF Risks

Yael L. Maxwell

August 04, 2022

News Daily News

HF Deaths on the Rise in Young Adults, US Data Show

L.A. McKeown

August 03, 2022

News Daily News

Early LV Recovery After TAVI Points to Better 5-Year Survival

Yael L. Maxwell

August 01, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Daily News

Black and Hispanic Patients Not Accessing High-Volume TEER Centers

Michael O'Riordan

July 19, 2022

News Daily News

Shock in Peripartum Cardiomyopathy Especially Risky in Black, Hispanic Patients

Caitlin E. Cox

July 13, 2022

News Daily News

Postop AF Portends Higher Risk of HF Hospitalization in the Next Few Years

Caitlin E. Cox

June 30, 2022

News Daily News

Heart Failure Risks of Smoking Can Linger for Decades

L.A. McKeown

June 07, 2022

News Conference News ESC Heart Failure 2022

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Shelley Wood

May 23, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Conference News HRS 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

Todd Neale

May 02, 2022

News Daily News

Infertility in Women Linked to Subsequent Risk of HFpEF

L.A. McKeown

April 19, 2022

News Daily News

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Caitlin E. Cox

April 15, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

L.A. McKeown

March 22, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

Advertisement

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

What’s Going to Be Hot at ESC 2022?

Women With Early Menopause See Higher Heart Failure, AF Risks

HF Deaths on the Rise in Young Adults, US Data Show

Early LV Recovery After TAVI Points to Better 5-Year Survival

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Black and Hispanic Patients Not Accessing High-Volume TEER Centers

Shock in Peripartum Cardiomyopathy Especially Risky in Black, Hispanic Patients

Postop AF Portends Higher Risk of HF Hospitalization in the Next Few Years

Heart Failure Risks of Smoking Can Linger for Decades

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Dapagliflozin Boosts Health Status Across LVEF Range

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

Infertility in Women Linked to Subsequent Risk of HFpEF

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

Guideline-Directed Therapies Underused in Frail HF Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content